WO2002058679A3 - Antiangiogenic compounds and an assay for inhibitors of cell invasion - Google Patents

Antiangiogenic compounds and an assay for inhibitors of cell invasion Download PDF

Info

Publication number
WO2002058679A3
WO2002058679A3 PCT/CA2002/000097 CA0200097W WO02058679A3 WO 2002058679 A3 WO2002058679 A3 WO 2002058679A3 CA 0200097 W CA0200097 W CA 0200097W WO 02058679 A3 WO02058679 A3 WO 02058679A3
Authority
WO
WIPO (PCT)
Prior art keywords
inhibitors
assay
cell invasion
compounds
antiangiogenic compounds
Prior art date
Application number
PCT/CA2002/000097
Other languages
French (fr)
Other versions
WO2002058679A2 (en
Inventor
Calvin Roskelley
Raymond Andersen
David Williams
Michel Roberge
Shoukat Dedhar
Aly Karsan
Andrew Minchinton
Original Assignee
Univ British Columbia
Calvin Roskelley
Raymond Andersen
David Williams
Michel Roberge
Shoukat Dedhar
Aly Karsan
Andrew Minchinton
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from CA002332138A external-priority patent/CA2332138A1/en
Application filed by Univ British Columbia, Calvin Roskelley, Raymond Andersen, David Williams, Michel Roberge, Shoukat Dedhar, Aly Karsan, Andrew Minchinton filed Critical Univ British Columbia
Priority to CA002435633A priority Critical patent/CA2435633A1/en
Priority to EP02711686A priority patent/EP1355893A2/en
Priority to AU2002231500A priority patent/AU2002231500B2/en
Priority to JP2002559013A priority patent/JP2004520372A/en
Publication of WO2002058679A2 publication Critical patent/WO2002058679A2/en
Publication of WO2002058679A3 publication Critical patent/WO2002058679A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/125—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/13—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/16—Masculine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/80—[b, c]- or [b, d]-condensed
    • C07D209/82—Carbazoles; Hydrogenated carbazoles
    • C07D209/86—Carbazoles; Hydrogenated carbazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the ring system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D225/00—Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom
    • C07D225/02—Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom not condensed with other rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Gynecology & Obstetrics (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

This invention provides the use of macrocyclic amines for inhibition of cellular invasion or angiogenesis. Compounds and pharmaceutical compositions of this invention are useful in the treatment of conditions characterized by cellular invasion or angiogenesis, including cancer. Compounds that may be used in this invention include the motuporamines.
PCT/CA2002/000097 2001-01-25 2002-01-25 Antiangiogenic compounds and an assay for inhibitors of cell invasion WO2002058679A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
CA002435633A CA2435633A1 (en) 2001-01-25 2002-01-25 Antiangiogenic compounds and an assay for inhibitors of cell invasion
EP02711686A EP1355893A2 (en) 2001-01-25 2002-01-25 Antiangiogenic compounds and an assay for inhibitors of cell invasion
AU2002231500A AU2002231500B2 (en) 2001-01-25 2002-01-25 Antiangiogenic compounds and an assay for inhibitors of cell invasion
JP2002559013A JP2004520372A (en) 2001-01-25 2002-01-25 Assay of anti-angiogenic compounds and inhibitors of cell invasion

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CA2,332,138 2001-01-25
CA002332138A CA2332138A1 (en) 2001-01-25 2001-01-25 Antiangiogenic compounds and an assay for inhibitors of cell invasion
US33067001P 2001-10-26 2001-10-26
US60/330,670 2001-10-26

Publications (2)

Publication Number Publication Date
WO2002058679A2 WO2002058679A2 (en) 2002-08-01
WO2002058679A3 true WO2002058679A3 (en) 2003-05-15

Family

ID=25682349

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CA2002/000097 WO2002058679A2 (en) 2001-01-25 2002-01-25 Antiangiogenic compounds and an assay for inhibitors of cell invasion

Country Status (4)

Country Link
EP (1) EP1355893A2 (en)
JP (1) JP2004520372A (en)
AU (1) AU2002231500B2 (en)
WO (1) WO2002058679A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9266815B2 (en) 2012-03-28 2016-02-23 University Of Central Florida Research Foundation, Inc. Anti-metastatic agents predicated upon polyamine macrocyclic conjugates

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5508188A (en) * 1994-01-21 1996-04-16 The Regents Of The University Of California Method of growing cells in a mammal
US5721226A (en) * 1993-03-10 1998-02-24 Magainin Pharmaceuticals Inc. Method for inhibiting angiogenesis using squalamine and squalamine steroid derivatives
WO1999035283A1 (en) * 1997-12-15 1999-07-15 Beth Israel Deaconess Medical Center Methods and reagents for modulating cell motility
WO2000021941A1 (en) * 1998-10-13 2000-04-20 Synchem Reserach, Inc. Biomimetic chelating agents and methods
WO2000043393A1 (en) * 1999-01-20 2000-07-27 Merck & Co., Inc. Novel angiogenesis inhibitors

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5721226A (en) * 1993-03-10 1998-02-24 Magainin Pharmaceuticals Inc. Method for inhibiting angiogenesis using squalamine and squalamine steroid derivatives
US5508188A (en) * 1994-01-21 1996-04-16 The Regents Of The University Of California Method of growing cells in a mammal
WO1999035283A1 (en) * 1997-12-15 1999-07-15 Beth Israel Deaconess Medical Center Methods and reagents for modulating cell motility
WO2000021941A1 (en) * 1998-10-13 2000-04-20 Synchem Reserach, Inc. Biomimetic chelating agents and methods
WO2000043393A1 (en) * 1999-01-20 2000-07-27 Merck & Co., Inc. Novel angiogenesis inhibitors

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
ALFRED BURGER ET AL.: "Some Derivatives of Cyclododecane", JOURNAL OF MEDICINAL CHEMISTRY, vol. 9, no. 6, November 1966 (1966-11-01), WASHINGTON US, pages 968 - 970, XP002195938 *
BARFACKER L ET AL: "One-Pot Synthesis of beta- and gamma-Aminofunctionalised Amines and Silanes via Hydroaminomethylation of Enamines and Vinylsilanes", TETRAHEDRON, ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL, vol. 55, no. 23, 4 June 1999 (1999-06-04), pages 7177 - 7190, XP004167090, ISSN: 0040-4020 *
CALVIN D. ROSKELLEY ET AL.: "Inhibition of Tumor Cell Invasion and Angiogenesis by Motuporamines", CANCER RESEARCH., vol. 61, no. 18, 15 September 2001 (2001-09-15), AMERICAN ASSOCIATION FOR CANCER RESEARCH, BALTIMORE, MD., US, pages 6788 - 6794, XP002195936, ISSN: 0008-5472 *
DAVID E. WILLIAMS ET AL.: "Motuporamines A-C, Cytotoxic Alkaloids Isolated from the Marine Sponge Xestospongia exigua (Kirkpatrick)", JOURNAL OF ORGANIC CHEMISTRY., vol. 63, no. 14, 1998, AMERICAN CHEMICAL SOCIETY. EASTON., US, pages 4838 - 4841, XP002195937, ISSN: 0022-3263 *
DAVID E. WILLIAMS ET AL.: "Motuporamines, Anti-Invasion and Anti-Angiogenic Alkaloids from the Marine Sponge Xestospongia exigua (Kirkpatrick): Isolation, Structure Elucidation, Analogue Synthesis, and Conformational Analysis", JOURNAL OF ORGANIC CHEMISTRY., vol. 67, no. 1, January 2002 (2002-01-01), AMERICAN CHEMICAL SOCIETY. EASTON., US, pages 245 - 258, XP002195935, ISSN: 0022-3263 *

Also Published As

Publication number Publication date
WO2002058679A2 (en) 2002-08-01
AU2002231500B2 (en) 2006-04-27
EP1355893A2 (en) 2003-10-29
JP2004520372A (en) 2004-07-08

Similar Documents

Publication Publication Date Title
IS6950A (en) Composition of epothilone analogues and chemotherapeutic agents for the treatment of cell proliferative disorders
WO2005023761A3 (en) Cytokine inhibitors
WO2001044247A3 (en) Agents and methods for the treatment of proliferative diseases
MXPA04001523A (en) Rapamycin dialdehydes.
IL157652A (en) Metalloproteinase inhibitors, compositions comprising them and uses thereof for the preparation of medicaments for treating diseases or conditions mediated by metalloproteinase enzymes
EP1628530B8 (en) Methods and compositions for the prevention and treatment of sepsis
WO2007106192A3 (en) Inhibitors of iap
WO2003088897A3 (en) Fab i inhibitors
WO2006023704A3 (en) Lonidamine analogues and their use in male contraception and cancer treatment
EP1608361A4 (en) Compositions of cyclooxygenase-2 selective inhibitors and 5-ht1b/1d agonists for the treatment and prevention of migraine
WO2006065820A3 (en) Pyrimidine inhibitors of erk protein kinase and uses therof
WO2004073623A3 (en) Treatment of conditions associated with decreased nitric oxide bioavailability, including elevated arginase conditions
TR200200821T2 (en) Derivatives of 5-beta-sapogen and pseudosapogen and their use in the treatment of dementia.
HUP0400193A3 (en) Imidazolindion derivatives as metalloproteinase inhibitors, their use and pharmaceutical compositions containing them
WO2004060890A8 (en) 2-oxopyridin-3-yl thia (di) azole derivates for use in the treatment of cell proliferation and apoptosis related diseases
WO2001052904A3 (en) Pharmaceutical compositions and methods of treatment based on VEGF antisense oligonucleotides
WO2004045557A3 (en) Novel lapachone compounds and methods of use thereof
TW200505443A (en) Combination of SCR kinase inhibitors and chemotherapeutic agents for the treatment of proliferative diseases
WO2002055530A3 (en) Transcobalamin binding conjugates useful for treating abnormal cellular proliferation
WO2007035709A3 (en) Novel crystal forms of irinotecan hydrochloride
WO2003028721A3 (en) Substituted benzimidazole compounds and their use for the treatment of cancer
WO2001087287A3 (en) Use of pyrazole derivatives for treating infertility
WO2004069160A3 (en) Chemical compounds
WO2005023191A3 (en) Rage-related methods and compositions for treating glomerular injury
WO2004087066A3 (en) Hif-1 inhibitors

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2435633

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2002559013

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2002711686

Country of ref document: EP

Ref document number: 2002231500

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 2002711686

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 2002711686

Country of ref document: EP